NCT01527032View on ClinicalTrials.gov

Risk-adapted Therapy for Primary Systemic (AL) Amyloidosis

PHASE2CompletedINTERVENTIONAL

Timeline

Start Date

September 30, 2002

Study Completion Date

September 30, 2005

Conditions

Amyloidosis

Interventions

DRUG

melphalan, thalidomide and dexamethasone

All Listed Sponsors

lead

FDA Office of Orphan Products Development

FED

NCT01527032 - Risk-adapted Therapy for Primary Systemic (AL) Amyloidosis | Biotech Hunter | Biotech Hunter